Mi SciELO
Servicios Personalizados
Revista
Articulo
Indicadores
- Citado por SciELO
- Accesos
Links relacionados
- Citado por Google
- Similares en SciELO
- Similares en Google
Compartir
Actas Urológicas Españolas
versión impresa ISSN 0210-4806
Resumen
QUEIPO ZARAGOZA, J.A. et al. Prognostic value for progression of the regulating proteins of the cellular cycle in PT1G3 bladder tumours. Actas Urol Esp [online]. 2005, vol.29, n.3, pp.261-268. ISSN 0210-4806.
Introduction and objective: Bladder tumor T1G3 constitutes the group of superficial tumors more aggressive. New prognostic factors in the field of the cytogenetics and molecular biology have been analyzed, with often contradictory results, being little the specific works in tumors T1G3. Our objective is to determine if in this group of tumors the immunohistochemical markers present predictive value of clinically useful progression, and therefore with validity to indicate more suitable a precocious therapeutic attitude Material and methods: Retrospective study of a series of 83 patients affected of bladder tumor T1G3, on which we analyzed a total of 14 variables; between the new predictive factors: the immunohistochemical determination of regulating proteins of the cellular cycle: p53, p21 and bcl-2, as well as the Ki-67 protein like marker of cellular proliferation. By means of logistic regression analisys we establish the independent prognostic variables for tumorlike progression. Results: The cut point established for Ki67 and p53 was 40% of inmmunomarked cells, 20% for p21 and 10% for Bcl-2. The univariant analysis showed different rates from progression and free times of progression based on the immunohistochemistry of Ki67 and p53; nevertheless, the logistic regression demonstrated that single the immunohistochemistry of p53 presented independent predictive value. Conclusions: The determination of p53 presents predictive value of clinically useful progression in bledder tumors T1G3, so that its determination can constitute a essential factor in the strategies of treatment of these tumors.
Palabras clave : T1G3; Inmunohistoquemistry; P53.